Pilne
Powrót do strony głównej
Wiadomości2 min czytania

Redakcja Today's Trending

Wiadomości o Semaglutide

Semaglutide jest na pierwszych stronach po relacjach The Times of India i innych mediów.

Zdjęcie: Ophthalmology Advisor. Image shown via the original publisher or news index. All rights belong to the respective copyright holder.

Udostępnij𝕏fWTin
Wiadomości o Semaglutide

Semaglutide stała się głównym tematem po pierwszych doniesieniach The Times of India.

Powiązane relacje

Zainteresowanie Semaglutide pokazuje, jak szybko wiadomość może zyskać zasięg. Co najmniej 2 mediów podało informacje.

Co podają media

Today's Trending będzie nadal śledzić tę historię i aktualizować relację.

Przypisane cytaty

“Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that…”

“Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating…”


Powiązane relacje

1. ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian…

Źródło: The Times of India

Przeczytaj całość →

2. A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG)…

Źródło: The South First

Przeczytaj całość →

Z naszej sieci

ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that Endoscopic Sleeve Gastroplasty (ESG), a non-surgical procedure, helped patients lose weight faster than oral semaglutide tablets in the short term. After a year, though, the difference narrowed.The AIG Hospitals study has been published in the peer-reviewed journal Endoscopy.As part of the study, researchers Dr D Nageshwar Reddy, Dr Nitin Jagtap, and Dr Rakesh Kalpala, compared 150 adults with obesity treated between January 2024 and April 2025. Around 50 patients underwent ESG, while 100 received oral semaglutide 14 mg along with standard lifestyle modification. At six months, patients who underwent ESG achieved an average total body weight loss of 12.72%, compared with 8.67% among those taking oral semaglutide. Around 70% of ESG patients lost at leas…

The Times of India

A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating obesity. Researchers found ESG produced greater weight loss at six months, while oral semaglutide largely caught up after one year. The findings highlight how treatment choice depends on patient goals, convenience and long-term care. An obese patient in Hyderabad asked a doctor a question that has become very common in recent times, "Should I undergo a procedure, or should I take a tablet?" Earlier, diet sheets and gym routines used to dominate conversations about obesity. Surgery waited at the far end, reserved for patients who had tried everything else. Now, that map has shifted. Patients weigh the stomach procedure against a hormone tablet. No one had tested the two against each other in the same group until doctors at AIG Hospitals in Hyderabad ran that…

The South First